Minoo Afshar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Minoo Afshar has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Zahra Jafariazar
Department of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
6 shared publicationsAzin Rezaeilaal
Department of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
2 shared publicationsBehrooz Gharib
Naft Hospital, Hematology and Oncology Department, Tehran, Iran
2 shared publications- Dora Molnar-Gabor
Dsm-firmenich, Kogle Allé 4, 2970, Hørsholm, Denmark
2 shared publications Farhad Shahi
Department of Medical Oncology, Tehran University of Medical Science, Tehran, Iran
2 shared publicationsLatifeh Navidpour
2 shared publications
Latest Publications
- 24 November 2022
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 396 (7) , 1571-1581
Pharmaceutical and clinical studies of celecoxib topical hydrogel for management of chemotherapy-induced hand-foot syndrome
Hand-foot syndrome (HFS) can be categorized as a frequent dose-limiting side effect following administration of chemotherapeutic agents, which needs an effective medication to avoid dose reduction or discontinuation. Oral celecoxib has been proved to be the best pharmacological intervention to ameliorate the skin lesions. However, due to reported gastrointestinal and cardiovascular toxicity following its long-term administration, celecoxib topical application would be a safe alternative for skin disorders. In this work, first, we formulated and optimized a topical hydrogel of celecoxib (1%) and then we investigated its efficacy in the management of chemotherapy-induced HFS in cancer patients. Optimized hydrogel showed acceptable results for drug content, pH, rheology, and stability. Analyzing in vitro drug release study by various mathematical models, the optimized hydrogel showed a zero-order release pattern with 93.27 ± 1.56% cumulative celecoxib release within 8 h. Ex vivo permeation studies across Wistar rat skin indicated suitable skin retention of celecoxib for topical delivery. Twenty-nine patients suffering from HFS were randomized to receive celecoxib and the placebo hydrogels 2 times a day for 3 weeks. At the baseline and at the end of the trial, HFS grades were determined. No serious adverse events occurred in patients who completely followed the instructions. No statistically significant differences between two arms were observed at the baseline (p value = 0.38). By contrast, Wilcoxon signed-rank test showed significant differences when secondary grades (p value = 0.05) and grade differences (p values < 0.001) were analyzed. Overall, the study proved that celecoxib hydrogel could be a promising intervention to manage HFS side effect. Graphical Abstract
- 24 November 2022
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 396 (7) , 1571-1581
Pharmaceutical and clinical studies of celecoxib topical hydrogel for management of chemotherapy-induced hand-foot syndrome
Hand-foot syndrome (HFS) can be categorized as a frequent dose-limiting side effect following administration of chemotherapeutic agents, which needs an effective medication to avoid dose reduction or discontinuation. Oral celecoxib has been proved to be the best pharmacological intervention to ameliorate the skin lesions. However, due to reported gastrointestinal and cardiovascular toxicity following its long-term administration, celecoxib topical application would be a safe alternative for skin disorders. In this work, first, we formulated and optimized a topical hydrogel of celecoxib (1%) and then we investigated its efficacy in the management of chemotherapy-induced HFS in cancer patients. Optimized hydrogel showed acceptable results for drug content, pH, rheology, and stability. Analyzing in vitro drug release study by various mathematical models, the optimized hydrogel showed a zero-order release pattern with 93.27 ± 1.56% cumulative celecoxib release within 8 h. Ex vivo permeation studies across Wistar rat skin indicated suitable skin retention of celecoxib for topical delivery. Twenty-nine patients suffering from HFS were randomized to receive celecoxib and the placebo hydrogels 2 times a day for 3 weeks. At the baseline and at the end of the trial, HFS grades were determined. No serious adverse events occurred in patients who completely followed the instructions. No statistically significant differences between two arms were observed at the baseline (p value = 0.38). By contrast, Wilcoxon signed-rank test showed significant differences when secondary grades (p value = 0.05) and grade differences (p values < 0.001) were analyzed. Overall, the study proved that celecoxib hydrogel could be a promising intervention to manage HFS side effect. Graphical Abstract
- 21 June 2021
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 40 (3) , 257-262
Efficacy of topical Lawsonia inermis L. (Henna) hydrogel in fluorouracil-induced hand-foot syndrome: a pilot randomized double-blind placebo-controlled clinical trial
Hand–foot syndrome (HFS) is a frequent dose-limiting adverse reaction of fluoropyrimidine drugs like capecitabine and 5-flourouracil (5-FU) in breast and gastrointestinal cancers. It has been shown...
- 21 June 2021
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 40 (3) , 257-262
Efficacy of topical Lawsonia inermis L. (Henna) hydrogel in fluorouracil-induced hand-foot syndrome: a pilot randomized double-blind placebo-controlled clinical trial
Hand–foot syndrome (HFS) is a frequent dose-limiting adverse reaction of fluoropyrimidine drugs like capecitabine and 5-flourouracil (5-FU) in breast and gastrointestinal cancers. It has been shown...
- 11 February 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 19 (10) , 2745-2751
Effect of monoterpenes on ex vivo transungual delivery of itraconazole for the management of onychomycosis
Background: Onychomycosis, a fungal nail infection, is an important problem as it may cause local pain, paresthesia, difficulties in performing activities of daily life, and impair social interactions. Systemic treatment of onychomycosis presents safety issues due to possible drug‐drug interactions and severe side effects. Although topical therapy of onychomycosis is advantageous due to its localized effect, the efficacy of such therapy depends on achieving effective concentrations of antifungal agents at the infection site. An approach to reach to this end would be driving benefit from synergic activity of antifungal agents for example itraconazole and monoterpenes. However, because of low transungual penetration of itraconazole, a molecule with high molecular weight and very low water‐solubility, the effect of the latter compounds on itraconazole nail delivery should be investigated, which was the aim of this study.Methods: Ex vivo permeation experiments were carried out through soaking the nail clippings of ten healthy volunteers in control and working solutions containing itraconazole (1 mg mL−1) and itraconazole (1 mg mL−1) plus 6% of each monoterpene including camphor, eucalyptol, menthol, and thymol, respectively, for 36 hours. The amount of itraconazole in nail clippings was quantified hereafter using a validated HPLC method.Results: Statistical analysis showed that itraconazole transungual permeation was not influenced by the studied monoterpenes (P value > .05).Conclusion: These results provided a new perspective for designing topical dosage forms for the treatment of onychomycosis.
- 11 February 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 19 (10) , 2745-2751
Effect of monoterpenes on ex vivo transungual delivery of itraconazole for the management of onychomycosis
Background: Onychomycosis, a fungal nail infection, is an important problem as it may cause local pain, paresthesia, difficulties in performing activities of daily life, and impair social interactions. Systemic treatment of onychomycosis presents safety issues due to possible drug‐drug interactions and severe side effects. Although topical therapy of onychomycosis is advantageous due to its localized effect, the efficacy of such therapy depends on achieving effective concentrations of antifungal agents at the infection site. An approach to reach to this end would be driving benefit from synergic activity of antifungal agents for example itraconazole and monoterpenes. However, because of low transungual penetration of itraconazole, a molecule with high molecular weight and very low water‐solubility, the effect of the latter compounds on itraconazole nail delivery should be investigated, which was the aim of this study.Methods: Ex vivo permeation experiments were carried out through soaking the nail clippings of ten healthy volunteers in control and working solutions containing itraconazole (1 mg mL−1) and itraconazole (1 mg mL−1) plus 6% of each monoterpene including camphor, eucalyptol, menthol, and thymol, respectively, for 36 hours. The amount of itraconazole in nail clippings was quantified hereafter using a validated HPLC method.Results: Statistical analysis showed that itraconazole transungual permeation was not influenced by the studied monoterpenes (P value > .05).Conclusion: These results provided a new perspective for designing topical dosage forms for the treatment of onychomycosis.
- 1 September 2019
- Published by Elsevier in Journal of Herbal Medicine
- Vol. 17-18
Clinical efficacy of a topical polyherbal formulation in the management of fluorouracil -associated hand-foot syndrome
- 1 September 2019
- Published by Elsevier in Journal of Herbal Medicine
- Vol. 17-18
Clinical efficacy of a topical polyherbal formulation in the management of fluorouracil -associated hand-foot syndrome
- Open Access
- 1 June 2019
- Published by CMV Verlag in MEDICAL SCIENCES JOURNAL
- Vol. 29 (2) , 117-124
Formulation and in vitro evaluation of orally disintegrating film of alprazolam
Background: Over the past years, orally disintegrating films (ODFs) have been a suitable alternative to conventional oral dosage forms such as tablets and capsules, especially for patients with dysphagia. ODF is relatively a new dosage form which is prepared using hydrophilic polymers, which rapidly dissolve on tongue or buccal cavity and has ...
- 1 June 2019
- Published by CMV Verlag in MEDICAL SCIENCES JOURNAL
- Vol. 29 (2) , 117-124
Open AccessFormulation and in vitro evaluation of orally disintegrating film of alprazolam
Background: Over the past years, orally disintegrating films (ODFs) have been a suitable alternative to conventional oral dosage forms such as tablets and capsules, especially for patients with dysphagia. ODF is relatively a new dosage form which is prepared using hydrophilic polymers, which rapidly dissolve on tongue or buccal cavity and has ...
- 30 September 2018
- Published by Oxford University Press (OUP) in Journal of Pharmaceutical Health Services Research
- Vol. 10 (3) , 359-364
Quality assessment of nifedipine cream compounded by retail pharmacies in Tehran
- 30 September 2018
- Published by Oxford University Press (OUP) in Journal of Pharmaceutical Health Services Research
- Vol. 10 (3) , 359-364
Quality assessment of nifedipine cream compounded by retail pharmacies in Tehran